ANALYSIS OF RISK-FORMING FACTORS FOR MERCHANDISE RETURN IN THE PHARMACEUTICAL PRODUCT MOVEMENT NETWORK

DOI: https://doi.org/None
Issue: 
4
Year: 
2015

N.V. Chukreeva, PhD; Professor E.A. Maksimkina, PhD I.M. Sechenov First Moscow State Medical University; 8, Trubetskaya St., Build. 2, Moscow 119991

Good global pharmaceutical practices (good distribution practice and good pharmacy practice) operating in the drug movement network were studied. Internal and external risk-forming factors in the processes occurring in the drug delivery network were identified. Using the merchandise returning process as an example, the authors analyzed the potential reasons for returning the supplier the drugs offered by a previous distributor. To analyze the risks of the processes, they proposed to use the Ishikawa (fishbone) diagram recommended by the International Conference on Harmonization documents. The authors revealed the efficiency of brainstorming and defined diagram construction staging. It was concluded that there were potential hazards due to organizational incidents; negative processing tendencies, irrational decisions made under the uncertainties frequently associated with the lack of standardized execution of actions as standard operating procedures. The timely identification of risk factors in all drug movement processes is a key prerequisite for making risk management decisions to minimize potential hazards to the life and health of patients and to the property interests of the subjects of the goods movement network.

Keywords: 
medicines
global goods movement network
quality system
risk management
business processes
standard operating procedures
merchandise return

References: 
  1. Strategiya lekarstvennogo obespecheniya naseleniya Rossiyskoy Federacii do 2025 goda. Ministerstvo zdravoohraneniya RF. Prikaz N 66 ot 13 fevralya 2013 g. «Ob utverzhdenii strategii lekarstvennogo obespecheniya naseleniya Rossiyskoy Federacii na period do 2025 goda i plana ee realizacii».[Strategy for pharmaceutical provision of the RF population until 2025. Russian Federation Ministry of Healthcare. Order dated № 66 13 of February 2013 «About approval of the strategy for pharmaceutical provision of the RF population until 2025 and schedule of its implementation» (in Russian)].
  2. Chukreeva N.V. Metodicheskiy podhod k sozdaniyu modeli upravleniya kachestvom processov tovarodvizheniya lekarstvennyh sredstv. «Sovremennaya medicina i farmacevtika: analiz i perspektivy razvitiya»: materialy VIII Mezhdunarodnoy nauchno-prakticheskoy konferencii. (2013 g.) M.: «Sputnik +», 2013: 30–34 [Chukreeva H.V. Methodical approach for the implementation of the modeling for quality management of the processes in pharmaceutical Supply Chain. «Modern medicine and pharmaceutics: analysis and development perspectives»: VIII international scientific-practical conference (2013) – Moscow, “Sputnik + “, 2013: 30–34 (in Russian)].
  3. European Commission Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (Text with EEA relevance) (2013/C 343/01). Official Journal of the European Union, 343/1–343/14.
  4. ICH Harmonized Tripartite Guideline. Pharmaceutical Development Q8. Current Step4 version dated August 2009: 24.